The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1496
Alternatives to Fluoroquinolones
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has announced that it is requiring changes in the labeling of systemic fluoroquinolones to warn that the risk of serious adverse effects, including tendinitis, peripheral neuropathy and CNS effects, generally outweighs their benefit for the treatment of acute sinusitis, acute exacerbations of chronic bronchitis, and uncomplicated urinary tract infections. For these infections, the new labels will recommend reserving fluoroquinolones for patients with no other treatment options.1

SINUSITIS — Acute sinusitis in adults is often viral and symptoms can be managed with analgesics, a nasal corticosteroid, and/or nasal saline irrigation. When it is bacterial, it is generally caused by Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis and can be treated with amoxicillin or amoxicillin/clavulanate. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Alternatives to Fluoroquinolones
Article code: 1496c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian